TENX Second Quarter Results
| TENX Stock | USD 6.41 0.13 2.07% |
Slightly above 56% of all Tenax Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Tenax Therapeutics suggests that some traders are interested. Tenax Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tenax Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tenax |
By John Vandermosten, CFA NASDAQTENX READ THE FULL TENX RESEARCH REPORT Second Quarter Financial and Operational Review Tenax Therapeutics, Inc. reported 2Q23 results on August 14, 2023 via its filing of Form 10-Q with the SEC. Despite the slow pace of advancement, we are impressed with the clinical data for both of Tenax PAH assets levosimendan and imatinib. We see tremendous
Read at finance.yahoo.com
 |
Tenax Therapeutics Fundamental Analysis
We analyze Tenax Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenax Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenax Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Tenax Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Tenax Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenax Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenax Therapeutics could also be used in its relative valuation, which is a method of valuing Tenax Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenax Therapeutics Related Equities
| UNCY | Unicycive Therapeutics | 2.63 | ||||
| NRBO | Neurobo Pharmaceuticals | 0.00 | ||||
| ALLR | Allarity Therapeutics | 0.98 | ||||
| QNRX | Quoin Pharmaceuticals | 1.49 | ||||
| ZVSA | ZyVersa Therapeutics | 1.60 | ||||
| WINT | Windtree Therapeutics | 3.23 | ||||
| DRMA | Dermata Therapeutics | 3.55 | ||||
| REVB | Revelation Biosciences | 4.69 | ||||
| ENSC | Ensysce Biosciences | 4.87 | ||||
| ADTX | Aditxt | 5.00 | ||||
| SONN | Sonnet Biotherapeutics | 6.32 | ||||
| VRAX | Virax Biolabs | 10.93 |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.